NASDAQ · VTRS

Viatris Inc.

$17.24 -$0.04 (-0.23%) 1D After hours
Charting by TradingView

Key Metrics

$20.12B
Market cap
—
P/E · TTM
$14.56B
Revenue · TTM
−$3.51B
Net income
EPS · TTM $-2.95
Dividend yield —
Free cash flow $1.79B
Beta · 1Y 0.71
EBITDA · TTM $1.99B
Gross margin 34.4%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 7
    The stock moved +9.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 7

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$20.12B
Enterprise value$32.66B
Shares outstanding1.2B
52-wk range$8.63 – $17.68
Avg volume · 20D10.2M
Net cash −$12.54B
Book value / share$12.29
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Viatris Inc.
IPO dateFeb 23, 1973
Employees30000

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S1.38
P/FCF11.23
EV/EBITDA16.38
EV/Sales2.24
Graham №—

Profitability

Gross 34.4%
Operating -5.6%
Net -24.1%
FCF 12.3%
ROE / ROIC -24.0% · -1.1%

Financial Health

Current ratio1.60
Quick ratio1.03
Debt / equity0.98
Debt / EBITDA 7.19
Net cash −$12.54B
Working capital$4.11B

Cash Flow · TTM

Operating CF $2.17B
Capex −$376.10M
Free cash flow $1.79B
Buybacks $325.10M
Dividends paid —
Shareholder yield 1.6%

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

1.0
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings